Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7349 5157
Tel: +81 (0)80-1164-4754
Request a Demo
What our customers are saying
When I think of the future, I think of EvaluatePharma
Global pharmaceutical company
EvaluatePharma Changes Company Name to Evaluate
Change reflects expanding portfolio of life science market intelligence and analysis services
LONDON and BOSTON (April 16, 2013) — EvaluatePharma Ltd, publisher of EvaluatePharma®, has changed its company name to Evaluate Ltd. The new name supports the company’s expanding coverage to broader life science markets. Evaluate’s current services include EvaluatePharma® for the biotech and pharma sectors, EvaluateMedTech™ for the medical device and diagnostic industries, and EvaluateClinical Trials™ for global clinical trial coverage.
“Adopting our new name, Evaluate, showcases one of our core competencies – evaluation of commercial performance - while maintaining continuity with our growing portfolio of services that our customers have come to know,” said Evaluate COO Alexander Karle. “It also reflects our primary objective of responding to our clients’ needs, and effectively delivering a new level of intelligence required to add value to their business.”
Evaluate’s current services include:
- EvaluatePharma – Delivers exclusive, trusted commercial insight into pharma and biotech industry performance through reliable consensus forecasts to 2018, standardized, fully transparent data and time-saving evaluation tools to help increase your competitive edge.
- EvaluateMedTech – Provides unique insights into the medical device and diagnostic industry through consensus forecasts, regulatory approvals and clinical trials data, press releases and deals to help you compete effectively in the global market.
- Evaluate ClinicalTrials –Brings confidence and speed to your analysis of the complex global clinical trials landscape linking ClinicalTrials.gov, EudraCT and Japanese clinical trial data to give you the very latest intelligence.
- EP Vantage – Tells you what's important and what you should be paying attention to through its award-winning daily commentary and analysis that provides keen insights as to current and future industry triggers.
Established in 1996, Evaluate is the leader in high quality life science sector analysis. EvaluatePharma delivers exclusive consensus forecasts and trusted commercial insight into biotech and pharmaceutical performance. EvaluateMedTech sets a new standard in integrated analysis and consensus forecasts of the global medical device and diagnostic industry. EvaluateClinical Trials delivers unique intelligence to efficiently and accurately analyze the global clinical trial landscape. A team of over 85 dedicated healthcare analysts employ rigorous methodologies to collate, organize and deliver the most-up-to-date commercial performance data available. An award winning editorial team of journalists writing under the EP Vantage name support EvaluatePharma’s analysis. The Evaluate services enable the life science community to make sound business decisions about value and opportunity.
For more information please visit www.evaluategroup.com.
On Twitter: @evaluatepharma, @evaluatemedtech, @epclinicaltrial, @epvantage.
Back to press releases